Tremelimumab is a monoclonal antibody directed against CTLA-4 that showed safety and manageable toxicity in advanced HCC patients not responding or intolerant to Sorafenib, while achieving a median OS of 15 months [13]. Here, CTLA4 is linked to hepatocellular carcinoma.